Structure Therapeutics, Inc.: Promising Advances in Metabolic Treatments Drive Buy Recommendation
BMO Capital analyst Evan Seigerman has reiterated their bullish stance on GPCR stock, giving a Buy rating on November 5. Evan Seigerman has ...
Schrodinger’s Promising Growth Potential Highlighted by Novartis Partnership and Strong Fundamentals
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...
BioSpace8d
Gilead Beats Q3 Expectations Fueled by HIV Drug Sales, Raises Full-Year Guidance
BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...
Hosted on MSN1mon
Pfizer needs to 'fix what they have', no M&A capacity, says BMO's Evan Seigerman on activist stake
Evan David Seigerman, BMO Biotech Analyst, joins 'Closing Bell Overtime' to talk Pfizer shares climbing on activist firm Starboard taking a stake in the company. Kamala Harris Gets Good News in ...
BioSpace15d
Amgen Whets Investors’ Appetites for MariTide Obesity Data by End of Year
While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on ...
Benzinga.com11mon
Evan David Seigerman's Stock Ratings
Evan David Seigerman is an analyst at BMO Capital. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected ...
Seeking Alpha17d
Amgen Q3 2024 Earnings Preview: All eyes on obesity candidate data
Investors and analysts will be looking for updates on the mid-stage trial of Amgen’s (AMGN) lead weight loss candidate, MariTide, although BMO Capital Markets’ Evan David Seigerman does not ...